Humana (NYSE:HUM) Posts Earnings Results, Beats Expectations By $0.10 EPS

Humana (NYSE:HUM) released its earnings results on Tuesday. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10, Zacks reports. Humana had a return on equity of 13.20% and a net margin of 1.18%. Humana updated its FY 2025 guidance to 16.250-16.250 EPS.

Humana Stock Down 3.8 %

Shares of Humana stock opened at $256.69 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The business has a 50-day moving average of $273.00 and a 200-day moving average of $295.72. The company has a market capitalization of $30.91 billion, a PE ratio of 22.74, a P/E/G ratio of 2.11 and a beta of 0.56.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Morgan Stanley cut their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Truist Financial boosted their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Piper Sandler increased their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, TD Cowen boosted their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $296.84.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.